Core Viewpoint - Tianyuan Medical (00557) anticipates a significant decline in total revenue for the first half of 2025, projecting approximately HKD 8.4 million, a year-on-year decrease of about 44% [1] Revenue Forecast - The expected decrease in total revenue is primarily attributed to the suspension of operations and renovations at Shanghai Yuyue Weilai Medical Beauty Hospital, which is partially owned by the group, leading to a projected revenue drop of at least HKD 6.2 million to around HKD 0.5 million (previous period: approximately HKD 6.7 million) [1] Net Loss Projection - The group expects to incur a net loss of approximately HKD 8.4 million during the interim period (previous period: approximately HKD 9 million) [1] - The estimated net loss is mainly due to the anticipated reduction in total revenue compared to the previous period, offset by a corresponding decrease in operating costs [1]

Core Viewpoint - Tianyuan Medical (00557.HK) expects total revenue for the six months ending June 30, 2025, to be approximately HKD 8.4 million, a decrease of about 44% compared to approximately HKD 14.9 million in the previous period [1] Revenue Summary - The anticipated decrease in total revenue is primarily attributed to the suspension of operations and renovations at Shanghai Yuyue Weilai Medical Beauty Hospital, which is partially owned by the group, leading to a projected revenue drop of no less than approximately HKD 6.2 million to about HKD 500,000 (previous period: approximately HKD 6.7 million) [1] Net Loss Summary - The group expects to record a net loss of approximately HKD 8.4 million for the interim period (previous period: approximately HKD 9 million) [1] - The estimated net loss is mainly due to the anticipated decrease in total revenue, offset by a corresponding reduction in operating costs [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 中國天元醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：557） 盈利警告公佈 本公佈乃由中國天元醫療集團有限公司（「本公司」，連同其附屬公司統稱「本集 團」）董事（「董事」）會（「董事會」）根據香港聯合交易所有限公司證券上市規則 （「上市規則」）第13.09(2)(a)條及香港法例第571章證券及期貨條例第XIVA部項 下的內幕消息條文（定義見上市規則）而作出。 董事會謹此知會本公司股東（「股東」）及潛在投資者，根據對本集團最近期未經 審核綜合管理賬目的初步評估及本公司目前可獲得的資料，預期本集團於截至 二零二五年六月三十日止六個月（「中期期間」）將錄得總收益約8,400,000港元， 較截至二零二四年六月三十日止六個月（「前一期間」）的約14,900,000港元減少 約44%。預期總收益減少乃主要歸因於上海愉悅薇萊醫療美容醫院有限公司（本 集團擁有部分權益及位於中華人民共和國上海市的 ...

Core Viewpoint - Tianyuan Medical (00557.HK) will hold a board meeting on August 29, 2025, to review and approve the interim results for the six months ending June 30, 2025, and to consider the proposal for an interim dividend distribution, if any [1] Summary by Categories - Company Announcement - The board meeting is scheduled for August 29, 2025 [1] - The meeting will focus on the interim results for the six months ending June 30, 2025 [1] - The board will also consider the proposal for an interim dividend distribution [1]

CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：557） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因 依賴該等內容而引致之任何損失承擔任何責任。 承董事會命 中國天元醫療集團有限公司 執行董事 東薇 香港，二零二五年八月十四日 於本公告日期，本公司董事會由五名董事組成，其中東薇女士為執行董事；賀梅女士為非執 行董事；及阮國權先生、周思奇女士及李軍先生為獨立非執行董事。 董事會會議通告 中國天元醫療集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）謹此宣佈，本公司董事會將於二零二五年八月二十九日 （星期五）下午四時舉行會議，藉以（其中包括）審議及批准本集團截至二零二五 年六月三十日止六個月之未經審核中期業績及其刊發，以及考慮派發中期股息 （如有）。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國天元醫療集團有限公司 呈交日期: 2025年8月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00557 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | 本月底法定/註冊 ...

Core Viewpoint - Tianyuan Medical (00557) announced a capital increase agreement involving its indirect subsidiaries, which aims to enhance the operational capacity of Shanghai Rifu and strengthen the group's competitiveness in the medical services sector in China [1][3]. Group 1: Capital Increase Agreement - Hengqin Hanyue Mei will increase its investment in Shanghai Rifu by RMB 15.5152 million (approximately HKD 16.9116 million) through the conversion of debt into equity [1]. - Shanghai Huaman will contribute an additional RMB 10 million (approximately HKD 10.9 million) in cash to Shanghai Rifu [1]. - Following the capital increase, Shanghai Rifu's registered capital will rise from RMB 2.3846 million to RMB 27.8998 million, while the shareholding ratios of Hengqin Hanyue Mei and Shanghai Huaman will remain unchanged at 60.8077% and 39.1923%, respectively [1]. Group 2: Shareholder Loan Agreement - On July 21, 2025, Shanghai Huaman will provide a shareholder loan of RMB 3 million (approximately HKD 3.27 million) to Shanghai Rifu, with a loan term of 36 months [1]. Group 3: Strategic Collaboration - The capital increase and shareholder loan are designed to meet the operational funding needs of Shanghai Rifu, thereby providing additional working capital for its daily operations [3]. - The collaboration with Shanghai Huaman, a marketing company in the medical beauty sector, is expected to enhance the group's strategic value and create potential cooperation opportunities with other medical beauty centers in China [3]. - This partnership is anticipated to bring further support and resources to Shanghai Rifu and the overall group, driving growth momentum [3].

Group 1 - The core viewpoint of the articles highlights the recent performance and financial status of Tianyuan Medical, including its stock price increase and significant revenue decline [1][2]. - As of June 16, the Hang Seng Index rose by 0.7%, while Tianyuan Medical's stock price increased by 16.88% to HKD 0.9 per share, with a trading volume of 4,000 shares and a total turnover of HKD 3,600 [1]. - Over the past month, Tianyuan Medical has experienced a cumulative decline of 3.75%, but it has achieved a year-to-date increase of 48.08%, outperforming the Hang Seng Index by 19.11% [1]. Group 2 - Financial data indicates that for the year ending December 31, 2024, Tianyuan Medical reported total revenue of HKD 24.86 million, a year-on-year decrease of 40.65%, and a net profit attributable to shareholders of -HKD 31.71 million, reflecting a 121.12% decline [1]. - The company's gross profit margin stands at 79.11%, with a debt-to-asset ratio of 32.57% [1]. - Currently, there are no institutional investment ratings for Tianyuan Medical, and its price-to-earnings ratio (P/E) is -8.97, ranking 81st in the healthcare equipment and services industry, which has an average P/E of -22.06 [2]. Group 3 - Tianyuan Medical, previously focused on hotel management, has shifted its business direction under new major shareholder Tianyuan Manganese Group, aiming to become a leading medical management institution providing high-end and personalized medical services for female users [2].

Financial Performance - The company reported a net loss of approximately HKD 38.6 million for the fiscal year 2024, compared to a net loss of approximately HKD 27 million in the previous year, primarily due to an increase in goodwill impairment losses of HKD 23.5 million[4]. - The healthcare segment generated revenue of approximately HKD 7.6 million, down from HKD 25.6 million in the previous year, with a net loss of approximately HKD 12.4 million, a decrease of HKD 5.5 million from the previous year's loss[7]. - The investment holding segment reported a total net loss of approximately HKD 6.3 million, compared to HKD 3.1 million in the previous year, with a pre-tax loss of approximately HKD 18 million[5]. - The group's revenue for fiscal year 2024 was HKD 26,845,000, a significant decrease from HKD 45,230,000 in fiscal year 2023[17]. - Basic loss per share for the fiscal year 2024 was HKD 0.0858, with tangible net asset value per share decreasing from HKD 0.41 to HKD 0.39[10]. - The group reported a basic loss per share of HKD 8.58 for fiscal year 2024, compared to HKD 3.88 for fiscal year 2023[17]. - The group’s total assets decreased to HKD 260,934,000 in fiscal year 2024 from HKD 302,954,000 in fiscal year 2023[18]. - The group’s net assets decreased to HKD 175,951,000 in fiscal year 2024 from HKD 215,181,000 in fiscal year 2023[18]. Revenue and Business Segments - The Shanghai hospital generated revenue of approximately HKD 7.6 million in fiscal year 2024, down from HKD 25.6 million in fiscal year 2023, attributed to a slowdown in consumer demand due to macroeconomic conditions in China[22]. - The company plans to expand its medical and aesthetic services in China and other Asian markets, anticipating growth in consumer spending in the medical beauty industry[11]. - New skincare products, including the DA mask and the Poaoyan brand, were launched at the end of 2024, aimed at enhancing revenue streams from existing hospital services[11]. - The DA mask is specifically designed for post-operative use in aesthetic medicine, with plans for extensive promotion through Shanghai Hospital's customer channels[12]. - The Poaoyan brand focuses on post-aesthetic skincare products, targeting existing customers of Shanghai Hospital to convert them into seed users for the brand[12]. Corporate Governance - The company is committed to high standards of corporate governance, ensuring compliance with the corporate governance code and providing regular updates to the board on performance and financial status[41]. - The board consists of five members, including one executive director and three independent non-executive directors, ensuring a balanced governance structure[45]. - The company has adopted a standard code for securities trading by directors, confirming compliance throughout the review year[44]. - The board's primary functions include formulating corporate policies and strategies, overseeing business management, and ensuring alignment with the company's culture and values[48]. - The company regularly reviews its corporate governance practices to ensure adherence to the governance code[43]. - The Remuneration Committee, consisting of three independent non-executive directors and one executive director, was established to review and recommend senior management compensation proposals[55]. - The company ensures that no director or their associates participate in decisions regarding their own remuneration, maintaining fairness and transparency[62]. Risk Management and Internal Controls - The company has established a robust risk management and internal control system aimed at achieving strategic goals and safeguarding shareholder investments[74]. - The risk management framework includes a three-tier structure involving the board, audit committee, and senior management to enhance risk management across the organization[75]. - The audit committee is tasked with ensuring the effectiveness of financial reporting processes and internal controls, including compliance and risk management[65]. - The company has mechanisms in place for employees to confidentially raise concerns regarding financial reporting and internal controls[69]. - The company has established a risk management framework and conducts annual risk assessments to identify potential strategic, operational, financial, and compliance risks[81]. Environmental, Social, and Governance (ESG) Initiatives - The company has implemented a top-down ESG management approach, with the board responsible for setting ESG strategies and assessing risks[147]. - The group has committed to reducing emissions through various policies, including promoting cleaner energy and improving energy efficiency[158]. - The group emphasizes stakeholder engagement to enhance its ESG strategy and identify improvement opportunities[150]. - The group focuses on sustainable development and community engagement as part of its corporate responsibility initiatives[149]. - The group has maintained compliance with environmental regulations, reporting no significant violations related to emissions or waste management during the reporting period[154]. Employee and Workforce Management - As of December 31, 2024, the company had a total of 34 employees, a decrease from 59 employees in 2023, primarily due to high turnover influenced by the economic environment[181]. - The employee gender ratio in 2024 was 41% female and 59% male, compared to 32% female and 68% male in 2023[184]. - The overall employee turnover rate for the group was 15.9% in 2024, compared to 15.6% in 2023[198]. - The company emphasizes employee health and safety, providing various healthcare plans and regular emergency drills[199]. - The group adheres strictly to relevant occupational health and safety laws in China, including regulations specific to the medical beauty industry[200].

Financial Performance - The total revenue for the fiscal year ending December 31, 2024, was HKD 26,845,000, a decrease of 40.5% compared to HKD 45,230,000 in 2023[4] - The gross profit for the same period was HKD 21,238,000, down 24.1% from HKD 27,945,000 in the previous year[4] - The net loss for the fiscal year was HKD 38,606,000, compared to a net loss of HKD 26,957,000 in 2023, representing a 43.4% increase in losses[4] - The basic and diluted loss per share for 2024 was HKD 8.58, compared to HKD 3.88 in 2023, indicating a significant increase in per-share losses[4] - The company reported a total comprehensive loss of HKD 39,230,000 for the year, compared to HKD 26,841,000 in 2023, marking a 46.2% increase in comprehensive losses[5] - The company reported a pre-tax loss of HKD 34,238,000 for the year ended December 31, 2024, compared to a loss of HKD 15,484,000 in 2023, representing a year-over-year increase of 121.5% in losses[20] - The company recorded a net loss of approximately HKD 38.6 million for the fiscal year 2024, compared to a net loss of approximately HKD 27 million for the fiscal year 2023, primarily due to an increase in goodwill impairment losses of HKD 23.5 million[35] Asset and Liability Changes - Total assets decreased to HKD 261,469,000 in 2024 from HKD 298,023,000 in 2023, reflecting a decline of 12.3%[6] - Non-current assets decreased to HKD 86,147,000 in 2024 from HKD 121,700,000 in 2023, a decline of 29.2%[6] - The company's net asset value decreased to HKD 175,951,000 in 2024 from HKD 215,181,000 in 2023, a reduction of 18.2%[7] - Reportable segment assets decreased to HKD 259,290,000 in 2024 from HKD 301,133,000 in 2023, a reduction of 13.9%[14] - Reportable segment liabilities decreased to HKD 84,820,000 in 2024 from HKD 87,610,000 in 2023, a decline of 3.2%[14] - Accounts receivable decreased to HKD 7,960,000 in 2024 from HKD 13,188,000 in 2023, a reduction of 39.5%[25] - The company’s total receivables, including interest receivable, amounted to HKD 22,368,000 in 2024, down from HKD 27,379,000 in 2023, a decrease of 18.3%[25] - The company’s non-current receivables decreased to HKD 2,986,000 in 2024 from HKD 4,884,000 in 2023, reflecting a decline of 38.7%[25] - The company’s accounts payable decreased from HKD 4.326 million in 2023 to HKD 3.685 million in 2024[33] - The company’s other payables and accrued expenses increased from HKD 37.378 million in 2023 to HKD 40.206 million in 2024[33] Revenue by Segment - Medical service revenue decreased to HKD 9,254,000 in 2024 from HKD 27,366,000 in 2023, representing a decline of 66.1%[15] - The medical division generated revenue of approximately HKD 7.6 million in fiscal year 2024, down from HKD 25.6 million in the previous year, attributed to a slowdown in consumer demand due to macroeconomic conditions in China[37] - Interest income from third-party loans was HKD 17,591,000 in 2024, slightly down from HKD 17,864,000 in 2023, a decrease of 1.5%[15] - The company confirmed third-party loan interest income of HKD 17.6 million for fiscal year 2024, slightly down from HKD 17.9 million in the previous year[39] Goodwill and Impairment - The company's goodwill impairment loss for the year was HKD 23,473,000, which was not present in the previous year[4] - The goodwill impairment loss recognized was approximately HKD 23,473,000 due to declining revenue trends at the Shanghai hospital, influenced by macroeconomic challenges in China[24] - The company recorded a goodwill impairment loss of HKD 23,473,000 in 2024, with no such loss reported in 2023[13] Taxation and Dividends - The company did not make any provisions for Hong Kong profits tax in 2024 due to accumulated tax losses exceeding two years[18] - The effective tax rate for the company's Chinese subsidiaries remained at 25% for both years[18] - The company did not declare any final dividend for the year ended December 31, 2024, consistent with the previous year[21] - The board of directors has proposed not to declare a final dividend for the year ending December 31, 2024, consistent with the previous year[51] Business Strategy and Development - The company has identified four reportable segments: Investment Holding, Healthcare, Lending and Related Services, and Hotel Services, indicating a diversified business model[9] - The company is actively developing and expanding its core business in the medical and aesthetic surgery sectors in China and other Asian markets[41] - Management is actively seeking new business opportunities to diversify and increase revenue sources while developing existing business[46] - The group has launched comprehensive online promotions on platforms like Xiaohongshu and Douyin, and won the Bazaar Beauty Annual Award in 2024, enhancing brand influence and online visibility[43] - The group will continue its lending and related businesses in 2025, adopting more cautious credit assessments due to geopolitical tensions affecting global and Chinese macroeconomic conditions[44] - The group plans to hold various trading securities and will adjust its investment portfolio to adapt to economic conditions, aiming to improve investment returns through short-term investment plans[45] - The company plans to launch new skincare products by the end of fiscal year 2024, which are expected to become a new revenue source[38] Expenses and Cost Management - Depreciation and amortization expenses for reportable segments totaled HKD 7,979,000 in 2024, down from HKD 9,076,000 in 2023, a decrease of 12.1%[13] - The company’s prepaid expenses included approximately HKD 3,500,000 paid to business consultants for professional fees in 2024, down from HKD 5,400,000 in 2023[27]